Compare · AVTR vs PRPO
AVTR vs PRPO
Side-by-side comparison of Avantor Inc. (AVTR) and Precipio Inc. (PRPO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and PRPO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $10.56B, about 294.9x PRPO ($35.8M).
- AVTR has been more active in the news (8 items in the past 4 weeks vs 4 for PRPO).
- AVTR has more recent analyst coverage (25 ratings vs 0 for PRPO).
- Company
- Avantor Inc.
- Precipio Inc.
- Price
- -
- -
- Market cap
- $10.56B
- $35.8M
- 1M return
- +1.36%
- -
- 1Y return
- +35.05%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 8
- 4
- Recent ratings
- 25
- 0
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Precipio Inc.
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
Latest AVTR
- EVP, Chief Legal & Compliance Sokenu Claudius was granted 62,305 shares, increasing direct ownership by 25% to 313,533 units (SEC Form 4)
- EVP, Chief HR Officer Hankamer Brittany was granted 46,728 shares, increasing direct ownership by 19% to 295,592 units (SEC Form 4)
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by Avantor Inc.
- SEC Form 8-K filed by Avantor Inc.
- Avantor® Reports Third Quarter 2026 Results
- Avantor appoints new Chief Information Officer
- Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter
- Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026
- EVP and CFO Garner Todd W was granted 49,688 shares (SEC Form 4)
Latest PRPO
- SEC Form 8-K filed by Precipio Inc.
- Precipio Announces Q3-2026 Shareholder Update Call
- SEC Form 4 filed by Precipio Inc.
- SEC Form 4 filed by Precipio Inc.
- Precipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Precipio Announces Q2-2026 Financial Results
- Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Precipio Announces Q2-2026 Shareholder Update Call
- Director Valauri Christina Rizopoulos was granted 108 shares, increasing direct ownership by 2% to 5,628 units (SEC Form 4)
- Director Cossman Jeffrey was granted 416 shares, increasing direct ownership by 3% to 16,549 units (SEC Form 4)